Lundbeck says Alzheimer’s drug effective in trial

<p>COPENHAGEN (Reuters) – Danish drugmaker <span>Lundbeck</span> pronounced patients who took a Alzheimer’s drug claimant <span>Lu</span> AE58054 in a proviso 2 clinical hearing achieved statistically poignant alleviation in <span>cognitive performance</span> when a devalue was combined to <span>donepezil</span>.</p>
<p> Lundbeck pronounced a clinical investigate in 278 patients pang from Alzheimer’s illness had achieved a categorical <span>target</span> and that <span>Lu AE58054</span> was also well-tolerated in multiple with donepezil.</p>
<p> “These formula are really encouraging, and we are now evaluating how to best ensue with a growth of Lu AE58054,” <span>Anders Pedersen</span>, conduct of investigate and growth during Lundbeck, pronounced in a statement.</p>
<p> Lundbeck pronounced Alzheimer’s illness affects over 2...